Fortrea Holdings Inc. (FTRE)
- Previous Close
19.80 - Open
19.85 - Bid 19.78 x 800
- Ask 19.85 x 400
- Day's Range
19.52 - 20.18 - 52 Week Range
18.07 - 41.02 - Volume
1,577,599 - Avg. Volume
1,598,763 - Market Cap (intraday)
1.778B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.42 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.70
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
www.fortrea.comRecent News: FTRE
View MorePerformance Overview: FTRE
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FTRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FTRE
View MoreValuation Measures
Market Cap
1.78B
Enterprise Value
2.85B
Trailing P/E
--
Forward P/E
333.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.59
Price/Book (mrq)
1.22
Enterprise Value/Revenue
0.95
Enterprise Value/EBITDA
82.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.49%
Return on Assets (ttm)
-0.58%
Return on Equity (ttm)
-13.42%
Revenue (ttm)
3.01B
Net Income Avi to Common (ttm)
-215.5M
Diluted EPS (ttm)
-2.42
Balance Sheet and Cash Flow
Total Cash (mrq)
127.3M
Total Debt/Equity (mrq)
82.38%
Levered Free Cash Flow (ttm)
399.68M